Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 5100 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 7177 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 9616 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 11423 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 12347 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 14923 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 15671 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 16386 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 16812 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 17121 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 17172 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 17749 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 17995 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 18154 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 18266 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 18322 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 18543 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 19169 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 21420 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 22029 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 22919 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 24510 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 26448 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 29295 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | 31292 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | CORTISONE (M+CL)- | Peak area normalized | male | Pre-diabetic | Neuropathy |